You are here

GATC Health

 

GATC Health - A Game Changer In The Drug Development Sector

  • Discovering The Shortest Path to Better Drugs
    We believe GATC Health’s advanced AI platform creates
    safer, more effective therapeutics
    in record time.

    Become an Investor

  • GATC Health works to accelerate, optimize and
    de-risk drug discovery and development—creating
    tremendous value for our partners and customers.
    Our advanced technology closes the “AI Gap,”
    potentially saving years of R&D time and hundreds
    of millions of dollars per project.

    Become an Investor

 

GATC Health’s proprietary AI simulates individual human biology to:

  • Discover new drugs or repurpose existing drugs in record time
  • De-risk drug development and clinical trials
  • Assess individual health risks
  • Recommend the best treatment options

These breakthroughs are possible with GATC Health’s patented platform, which functionally acts like a digital humanoid. Drawing on large sets of public and proprietary multiomic data, our AI simulates human biology’s billions of interactions which, we believe, leads to the following: (i) rapid and accurate target discovery, (ii) drug identification, (iii) development and (iv) validation of safety and efficacy.

At the core of our work are two proprietary assets:

“Genomic stocks are in the first inning of a multi-year megatrend.”
-Forbes 2

Our Team

GATC Health is led by world-class scientists and seasoned finance professionals with over $12 billion combined funding. Prior to building GATC’s MAT platform, the firm’s experts developed some of the world’s best-known web-based technologies.

GATC Health’s leadership team intends to deliver value to shareholders and a clear path to an exit event.

Providing expert guidance to GATC’s management is the company’s Board of Advisors, which includes top researchers, medical doctors, employee benefits experts, biotech executives and government contracting experts.

GATC Health Management

John Stroh
Interim Chief Executive Officer

› 30+ years as an investment banker specializing in the health care sector

› CEO, Global Healthcare Advisors

› President & CEO, Nanospectra Biosciences

› COO, CFO & SVP, Kadmus Pharmaceuticals

› President, CEO & Director, Neomatrix LLC

Ian Jenkins
Chief Science Officer, Cofounder

› Developer of the science and process of GATC’s Predictive Multiomics™

› Co-creator of technology for Multiomics Advanced Technologies™

› Former researcher with the Human Genome Project

› VP Clinical Development, ORN Industries

Jayson Uffens
Chief Technology Officer, Cofounder

› VP Engineering, GrubHub

› Head of Engineering, Seamless

› Engineering Manager & Architect, Northrop Grumman Info Systems

› Senior Engineering Manager, GoDaddy.com

› Lead Application Architect, American Express

Preetaman Wadhwa
Chief Marketing Officer

› Global Market Lead, Oncology, Amgen

› Marketing Director, Cardiology, Amgen

› Masters Health Systems Management, Rush University

Eric Mathur
Chief Innovation Officer

› Founder of Stratagene (enabling PCR testing)

› Executive at Diversa Corp, largest biotech IPO at the time

› Recruited by Synthetic Genomics, lead researcher, purchased by Monsanto

› 50+ peer-reviewed publications and 100+ patents

Tyrone Lam
Chief Operating Officer

› Cofounder, COO, First Americans Health & Wellness

› Cofounder, COO, OneRecovery/OneHealth Solutions

› President, COO, NTN Buzztime

› VP Business Development, Predilytics

Chad Penry
Director of Business Development

› Founder, Quan Financial - business consulting & strategic partnerships

› Strategic partnerships with Fortune 500 companies, leading industry professionals, celebrities, artists, athletes, and non-profit organizations.

Jeff Moses
President

› Co-founder, CMO, director of PowerOne Energy Corp

› Multiple C-level positions with growth stage companies

› Founder & creative director of ad agency serving Fortune 500 clients

Kevin Woodbridge
Executive Vice President

› 30+ years in finance and corporate development

› Lead $100M+ financing for various companies

Michael Manahan
Interim Chief Financial Officer

› Professor Cal State University, Dominguez Hills, Entrepreneurial Finance

› President, Match Vest Capital

› Chief Financial Officer, BluTango Inc.

Industry-Leading Science, Technology and Business Advisors

Dr. Jonathan Lakey
Chair of Scientific Advisory Board

› Professor Emeritus, Surgery and Biomedical Engineering, University of California, Irvine

› Co-inventor of the “Edmonton Protocol” islet transplantation surgery for diabetes

› 500+ authored scientific papers

› International speaker

Patrick Lilley
Science Advisor

› CEO and Founder, Liquid Biosciences

› Inventor of over 75 trade secrets and patents

› Co-Chair Blockchain and AI Task Force

› Board Member, Mamogen, HepGene, LiquidLung

Dr. Chad Beyer
Science Advisor

› PhD, MBA, 25 years of CNS drug discovery and development experience

› 33 INDs; 70+ manuscripts; 2 blockbuster medications

› NIDA; Wyeth; Ariel and Promentis Pharmaceuticals

Dr. Jack Lewin
Science Advisor

› Chairman, National Coalition on Health Care, Washington DC

› Former CEO, American College of Cardiology

› Former President & CEO of Cardiovascular Research Foundation

Dr. Chitra Bhakta
Science Advisor

› Chronic disease specialist

› Physician at OC Integrative Medical Center

Dr. Stanley Lewis
Science Advisor

› Co-founder & CEO, A28 Therapeutics

› Former Chief Medical Officer, Ansun Biopharma

› Former Chief Medical Officer, TaliMed Biologics

› Director of Drug Development, Tanox

Dr. Negar Motoyagheni
Science Advisor

› Anesthesiology and Intensive Care TUMS/SBU, Scientist UCLA

› Regenerative Medicine Fellowship WFIRM

› 20+ academic certificates

Dr. David Kushner
Science Advisor

› 35+ years as Nuclear Radiology Specialist / US Navy Physician

› Fellow in Musculoskeletal imaging and Nuclear Medicine

› Assistant professor at Uniform University of the Health Science

Steve Lebedoff
Business Advisory Board Member

› President, BeneTrax, an Aon company (Global Risk and Benefit Consulting)

› Strategic Director, National Accounts (Fortune 500) Aon Worksite Solutions

› Assistant professor at Uniform University of the Health Science

› Executive Officer, PPN Health Access

› Co-founder, Center for Sustainable Healthcare, University of Nevada

Darius Naigamwalla
Business Advisory Board Member

› Executive Vice President, Two Labs Pharmaceutical

› Former CEO, CEEK Enterprises: BioPharma Consulting

› Former President, Campbell Alliance (now Syneos Health

›20+ years in BioPharma consulting & commercialization

Jim Arellano
Business Advisory Board Member

› President and Founder BP Insurance

› Former VP of National Accounts, United Health Group

› 35+ years’ experience in Healthcare Industry

LTC (R) Wade Jost
Military + Federal Advisor

› CEO, 640 Areas (Service-Disabled Veteran Owned Small Business

› U.S Army’s Rapid Equipping Forces (REF)

› Office of Secretary of Defense Joint IED Defeat organization

› U.S Military Academy of West Point

Mark Palaima
Technology Advisor

› eBay—Chief Architect, Fellow—10 yrs.

› Inkiru, Inc (Acquired by Walmart Labs)—Chief Scientist, Founder

› Ismintis Systems —Founder

 

GATC Health: Focused Advantage

Pharmaceutical R&D: Bridging the AI Gap for Drug Discovery

To our knowledge, GATC Health is the first company to bridge the AI Gap. But what is the AI Gap?

Traditionally, drug companies make assumptions about a disease and possible drug candidate molecules. This creates a giant haystack of data. They spend hundreds of millions of research dollars—and many years—analyzing each strand of “hay” trying to find the needle, or exact drug candidate.

Our competitors use AI to reduce the size of the haystack. At their best, they can reduce the haystack from 10,000 or more possible targets down to approximately 1,000. This can save several years and considerable expense—but it is only an enhancement to the traditional model.

The AI Gap is the difference between what our competitors deliver—a smaller haystack—and what GATC Health’s patented platform can deliver: the exact needle.

GATC Health skips the haystack and creates the needle.
 
 

Personalized Medicine: Genetics-Based Diagnostic Tools for Consumers

Creating new drugs starts with gathering data. Instead of paying for valuable biological data, GATC Health created a model for early disease detection and treatment optimization where customers pay us to collect their data. In turn, GATC provides a personalized, actionable report illustrating disease risk and recommended treatment options.

With a single cheek swab, our proprietary DNA test kits can identify your precise risks and recommended treatment for

  • Viral Immunity
  • Depression & Anxiety
  • Medical Cannabis
  • Health & Wellness

 

The company intends to complete the following diagnostic tools over the next 12 months:

  • Diabetes
  • Cardiac Health
  • Alzheimer’s
  • Parkinson’s
  • PTSD

 

GATC Health licenses these proprietary multiomic diagnostic tests to companies that distribute the products to consumers and physicians, enabling precision and predictive medicine across clinical settings.

New Drug Candidates in Months, Not Years

Via our relationship with Liquid Biosciences, world-class biomarker discovery company, GATC technology has created a new drug discovery platform. In our first project with Liquid Biosciences, GATC has:

  • Validated biomarkers for addiction
  • Discovered a new molecule for addiction treatment
  • We completed this work in a record breaking 9 months
  • Internal estimates of 50% or more reduction in drug discovery timeline
  • Net present value increase of over $500 million per drug, due to risk reduction, cost reduction and acceleration
  • Co-developed an AI-driven pipeline for new drug discovery, which has already produced multiple breakthrough molecules

Liquid Biosciences has completed over 192 projects with major pharmaceutical firms and research organizations for biomarker discovery, diagnostics, drug discovery, drug repurposing, database services, and analytics

 
 
What we do

Who Benefits from GATC Health’s Technology?

In short: everyone.
 

GATC Health Offering

Type:
Reg A + offering
 
Price:
$5.00 per share of Common Stock

 

$185,000,000 valuation (approximately 37 million shares issued and outstanding)

→ Invest in the Sector Forbes Called a “Multi-Year Megatrend”
Offering Circular

 

Mark Cuban, one of the most innovative and respected Internet-based entrepreneurs of our time, recently stated that artificial intelligence, “…will have a bigger impact on us than the Internet, than phones, mobile computing, mobile networking, wide-area networking—it’s just going to dwarf everything.” He went on to point out that, “…it’s harder to learn, harder to implement, and not everyone is going to be able to adapt…we are still in the first innings of the preseason game.”

As one of the richest people in the world, Bill Gates is known for contributing to global health through the Gates Foundation. As his biggest legacy, Microsoft is also moving in the same direction. The company is actively involved in helping the world’s population overcome some of the most challenging health problems and concerns.

Microsoft recently announced a new healthcare initiative known as “AI for Health,” a program worth over 40 million dollars. AI for Health evolved out of the AI for Good Program, which offers general aid to the less fortunate around the world.

 
The Market Opportunity

GATC Health sits at the center of four growing markets: genetic testing, AI in healthcare, personalized medicine and the world longevity economy.

Press

GATC Health in the News

image
GATC Health: Accurate, Personalized, and Predictive Insights into Human Biology

“Initially, the time taken to analyze the multiomic data set of an individual took about 165 hours. Today, the same can be completed in under five minutes and in parallel with millions of datasets due to GATC Health’s ability to process data increasing exponentially over the years.”

- Precison Medicine, October 2021
image
Artificial Intelligence That “thinks” Like Human Biology Advances Disease Detection, Treatment and Prevention

“Compared to traditional platforms that utilize artificial intelligence to accelerate mathematical, algorithmic models, GATC’S Multiomics Advanced Technology is at the forefront of a new model, where data is given biological context and value. With this distinct advantage, GATC Health provides exponentially faster, easier and more accurate results with far greater accuracy for disease detection, treatment, and therapeutics development.”

-Healthcare Business Today, May 2021
 

Competitors

As Genomics/AI companies continue to fetch huge valuations, GATC Health is uniquely positioned to flourish in these new economies. Our proprietary MAT AI/genomics platform and Predictive Multiomics database are proven to deliver groundbreaking results across a variety of lucrative applications advancing human health and scientific progress.

GATC Health’s Competitive Advantage

  • MAT AI provides superior biological context to omics data with the faster processing speed and scalability preferred by major industry partners.
  • The opportunity is immense. GATC’s technology can be taught to address nearly any condition, disease or disorder.
  • Our Predictive Multiomics database and MAT AI make us a complementary technology to others in this space. Companies that may have been competitors can now utilize our technology as partners.

Participate in the Future of Biotech With GATC Health

As the industry continues to push for expedited solutions for Emergency Use Authorizations, drug discovery, biomarker discovery, precision medicine, and more, GATC Health will continue to lead and innovate.

 

It’s an exciting time to be in biotech.

As a GATC Health investor, you’re in the perfect place at the perfect time. Will you step into the future with us?

Quotes from Advisors

Dr. Stanley Lewis

“I am excited to work with GATC’s team to identify and provide actionable data that benefits both patients and providers of care. GATC technology is perfectly aligned to provide the kind of relevant reports that give physicians and caregivers the information they need to optimize care plans.”
 

  • Co-Founder and CEO A28 Therapeutics
  • 20+ year biotechnology executive. Dr Lewis is the former CMO at TaiMed Biologics (public), Ansun Biopharma (private). Diabetes Relief (private) and Dir. of Drug Development at Tanox (sold to Genentech)
  • Developed TROGARZO(TM) from Phase 1 to FDA approval

Dr. Jack Lewin

“GATC’s mission to find earlier detection, prevention and treatment across the disease spectrum is backed by their talent and technology.”
 

  • Principal and Founder Lewin and Associates LLC
  • Chairman, National Coalition on Health Care, Washington DC
  • Former President and CEO of Cardiovascular Research Foundation

Dr. Jonathan Lakey

“GATC Health has presented me with an incredible opportunity to make significant advancements in the detection and treatment of diabetes. I have been tasked with assembling a world-class team of scientific and technical experts to further develop a diabetes-focused platform utilizing the company’s Multiomics Advanced Technology™ (MAT). The GATC Health diabetes platform has the potential to revolutionize the way we detect diabetes before it develops in an individual and possibly arrest its progression through new treatments and transplantation protocols.”
 

  • Professor Emeritus, Surgery and Biomedical Engineering
  • University of California Irvine
 

Updates

April 20
GATC Health Enters Oncology Drug Market with “Prodrugs for Cancer Treatment” Patent Application

GATC Health, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced it has filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. This breakthrough, produced by the company’s revolutionary Multiomics Advanced Technology™ AI platform, signals GATC Health’s entrance into the oncology drug discovery market.

 

Prodrugs are biologically inactive compounds which are metabolized in the body to produce a drug. Examples include aspirin, Plavix, and Prednisone. GATC Health’s unique new prodrug is designed to stimulate programed cell death in malignant cancer tissues and may serve as an effective therapeutic against glioblastoma brain tumors.

 

This novel mechanism of treatment has not been possible previously due to the difficulty of delivering and specifying the drug target interactions and has potential for an enhanced safety profile and improved selectivity. Additionally, this new prodrug format may considerably reduce the collateral damage caused by previous iterations of chemical agents used to treat cancers. The company expects this format to lead to many other breakthroughs in novel cancer therapeutics.

 

“I am very excited that we are continuing to expand our portfolio at GATC Health and entering in oncology with this innovative platform to meet unmet needs of cancer patients,” stated Preetaman Wadhwa, the company’s Chief Marketing Officer. “Glioblastoma accounts for half of all the cancerous brain tumors in adults. We see about 12 to 18 months average survival time for these patients with only 5% of patients surviving more than five years, highlighting the unmet need for innovation for these patients. Our new prodrug has the potential to differentiate between glioblastoma cells and healthy neuron growth, preventing replication of cancer cells for glioblastoma. This new technology may also be used for other tumors. Global spending on therapeutics and supportive care of cancer is continuing to grow and be is expected to reach $200 billion in 2022. With growing incidence of cancer in patients, oncology is the focus area for the 10 largest pharma companies, and we are looking forward to partnering with them to bring glioblastoma patients and other cancer patients a safe, effective cure.”

 

 

Disclaimer
The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.

March 15
Former eBay Chief Architect and Fellow, Mark Palaima, Joins GATC Health as Strategic Advisor

GATC Health, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced that Mark Palaima has joined the company as Strategic Advisor. Mr. Palaima will apply his 35+ years of leadership in large-scale software and systems to support the company in strategic planning and partnerships.

Mr. Palaima spent a decade building and scaling eBay’s technology and systems.  His career spans multi-discipline engineering positions encompassing database technologies, complex analysis & modeling, global eCommerce, large-scale system integrations, predictive intelligence, virtual retinal display technology, embedded sensor and microcontroller products, and industrial automation.

“During Mark’s tenure as Chief Architect at eBay, he led their Kernel and Architecture teams through multiple generations of eBay technology, supporting eBay’s meteoric growth, business expansion, partnerships, and acquisitions,” noted Jayson Uffens, GATC Health’s Chief Technical Officer. “We are tapping into his expertise in scaling compute and storage platforms, as well as data acquisition strategies, to drive down costs and ensure best-value relationships with all partners, licensees, and suppliers.”

“When I was first introduced to GATC Health, I quickly understood just how valuable their platform could be in advancing the quality of healthcare,” stated Mr. Palaima. “This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief. I am extremely excited to work with this talented team and help introduce their AI platform to the world.”

 

Disclaimer
The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This announcement contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.

February 19
Predictive Test for Type 2 Diabetes Developed by GATC Health Could Be Industry First

GATC Health Corp, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced it has filed a provisional patent for a lateral flow assay that identifies individual risk of diabetes and predicts the likely rate of progression for those at risk. The company believes this is the first predictive tool for Type 2 diabetes risk. The 15-minute test is designed to help doctors and patients improve early prediction and treatment of diabetes, including the potential to delay the onset of the disease for higher risk individuals.

According to the Centers for Disease Control and Prevention (CDC) the total annual cost of diabetes in the U.S. alone is $327 billion with $1 out of every $4 in US health care costs spent on caring for people with diabetes.

Unlike current diabetes tests that only detect whether an individual already has the disease, GATC Health’s test has the potential to predict the individual’s future risk of developing diabetes. In addition, the test can be used as a tool to delay or prevent the onset of the disease with additional lifestyle or medical interventions.

Currently, there are no clinically validated tests which identify people predisposed with contracting diabetes. Diabetes tests today—including A1C, Fasting Blood Sugar, Glucose Tolerance and Random Blood Sugar—only determine if the patient is already diabetic or prediabetic. Unfortunately, individuals testing positive for the disease by these tests are beyond the point of prevention and must focus on treatment. Diabetes is currently detected via blood tests or continuous glucose monitors which measure current levels of HbA1C, or glucose in the bloodstream. GATC Health is directly addressing this gap in the market with this predictive test for Type 2 diabetes.

The company developed this test using its proprietary artificial intelligence platform, Multiomics Advanced Technology™ (MAT). MAT can analyze all biological data sets (multiomics), including genomic data, allowing the GATC scientific team to a create a holistic multiomics system specific to diabetes. The system identified and extrapolated the key markers in the progression of the disease, which are then quantified in this test. GATC Health expects that once available, it will provide potentially life-changing information to physicians and their patients, as well as providing significant benefits to risk-bearing parties, like insurance companies.

“Over my history of diabetes research, we have been searching for key predictive factors that help identify those who are at higher risk of developing diabetes in the future. This significant discovery will dramatically improve diabetes diagnostic predictive testing which can be used to initiate protocols to delay or prevent the development of the disease entirely,” said Dr. Jonathan Lakey, Chair of GATC Health’s Scientific Advisory Board and Professor Emeritus Departments of Surgery and Biomedical Engineering, University of California Irvine. “I believe we have identified a new, highly effective tool that could substantially reduce the incidence and impact of diabetes worldwide.”

In development for over a year, the diabetes lateral flow test is built upon Dr. Lakey’s many years of research in diabetes at University of California Irvine and his interest in the effect of diabetes on a growing segment of the world’s population. GATC Health has leveraged research, case studies and numerous data sets in conjunction with its MAT platform to develop early models that identify a longer term of pathology and predictive pathways. This groundbreaking test further illustrates GATC Health’s commitment to advancing predictive medicine and accelerating drug discovery..

“This unique use of biomarker quantification in a lateral flow test for type 2 diabetes is further evidence that GATC Health’s advanced AI platform has the capability to improve patient care in powerful, non-obvious ways,” said Ian Jenkins, GATC Health’s Chief Scientific Officer. “We are also optimistic this discovery can be used as a companion diagnostic for potential drug candidates in our product pipeline.”

GATC Health’s diabetes lateral flow test will utilize a finger prick to extract a drop of blood that is processed using a cassette that is similar in appearance to a pregnancy test. The test will then be processed at either a clinician’s office or mailed to a certified laboratory and read using a relatively inexpensive standard laser plate reader.

GATC Health is in the process of engaging partners to develop a prototype for pre-clinical testing, clinical trials, and necessary regulatory approvals.

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

February 18
Chad Beyer Joins GATC Health Corp’s Scientific Advisory Board to Enhance Drug Discovery Team

GATC Health, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced that Chad Beyer, PhD, MBA, has joined the company as Science Advisor to further enhance the drug discovery team. Dr. Beyer has nearly 25 years of experience in the discovery, research, and clinical development of diseasemodifying medications. Currently, Dr. Beyer is Senior Vice President of Research and Development at Promentis Pharmaceuticals. Prior to heading up the R&D group at Promentis, Dr. Beyer was the SVP of R&D at Ariel Pharmaceuticals and Head of Neurochemistry at Wyeth Pharmaceuticals.

“Dr. Beyer’s proven leadership of successful preclinical and clinical drug discovery teams is a significant addition for GATC Health,” stated Dr. Jonathan Lakey, Chair of GATC Health’s Scientific Advisory Board. “His passion for GATC Health’s platform capabilities to accelerate the drug discovery process further validates our value.”

During his career, Dr. Beyer has led several preclinical and clinical drug discovery teams, participated in the submission of more than 33 INDs, and worked with a group responsible for contributing to the commercialization and life-cycle management of two blockbuster medications: Effexor® and Pristiq®.

Dr. Beyer holds a Ph.D. in neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. He has served on the Board of Directors of various companies including a non-profit organization focused on childhood cancer. Notably, Dr. Beyer has authored more than 70 manuscripts, co-edited the book entitled “Next Generation Antidepressants” and co-founded the journal “Technology Transfer & Entrepreneurship.” In addition, Dr. Beyer holds several adjunct faculty positions and is the ‘Entrepreneur in Residence’ at Lafayette College where he teaches Biotech Innovation, a course focused on entrepreneurship and “the business of science."

“Successfully translating preclinical findings to effective medicines for humans is difficult and hugely complex work. New tools to more efficiently and precisely discover a new generation of medicines are crucial and the team at GATC Health are at the leading-edge of such new AI and machine learning technologies,” stated Dr. Beyer. “I am excited to join GATC's Scientific Advisory Board to further advance their mission of developing AI-derived therapies for horrible and devastating diseases including addiction and substance use disorders.”

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

February 16
GATC Health to Present at the Emerging Growth Conference on February 16, 2022 at 1:00 p.m. EST, Highlighting Its AI-Powered Drug Development Multiomics Platform

GATC Health to Present at the Emerging Growth Conference on February 16, 2022 at 1:00 p.m. EST, Highlighting Its AI-Powered Drug Development Multiomics Platform

GATC Health Corp invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.

GATC Health Corp, a privately-held biotech company using artificial intelligence, genomics and advanced biological data to revolutionize drug discovery and disease prediction, is pleased to announce that it has been invited to present at the Emerging Growth Conference on February 16, 2022 at 1:00 p.m. EST.

This live, interactive online event will allow existing shareholders, prospective shareholders, and the investment community to interact with the Company’s Chief Operating Officer, Mr. Tyrone Lam, and Chief Marketing Officer, Ms. Preetaman Wadhwa, in real-time.

GATC Health will present its leading-edge solution to create safer, more effective therapeutics in record time using its advanced AI platform. The company may subsequently open the floor for questions. Questions not answered during the live presentation may be addressed by the company after its presentation through email.

 

GATC Health will be presenting at 1:00 p.m. Eastern time for 30 minutes.

Please register HERE to ensure you can attend the conference and receive any released updates.

(please register through the hyperlink provided above)

If attendees cannot join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com, and we will also release a link to that after the event.

 

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services, and other major announcements to the investment community from the convenience of their office, in a time-efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, investment advisors, and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

*   *   *

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

February 08
GATC Health Files Suite of Patents for Multiomics-Based Predictive Disease Detection and Treatment

GATC Health Corp, a technology company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced it filed five patent applications with the US Patent and Trademark Office. These patent applications represent productizations of the company’s groundbreaking Multiomics Advanced Technology™ (MAT) to address individuals’ viral immune response, cardio-pulmonary risk, depression and anxiety treatment, medical cannabis treatment and medical psilocybin treatment.

“Each of these ‘engines,’ as well call them, represents a dual opportunity for our company. First, we provide personalized early diagnostic and treatment tools to healthcare providers, clinicians and patients through value-added channel partners. Second, we are continually collecting extremely valuable multiomics data. This proprietary data fuels our drug discovery and development efforts by improving our AI platform, as well as providing a significant revenue stream,” stated Jeff Moses, President of GATC Health.

Unlike other DNA-based diagnostic tools, GATC Health’s engines analyze billions of biological data points. Competitors typically rely on low-cost SNP chip methods, which usually analyze hundreds of thousands of data points. GATC Health’s diagnostic and treatment engines use a combination of whole genome or exome analysis and other pertinent omic information, such as metabalomic, proteomic, transcriptomic or epigenomic data, to provide actionable, personalized reports for patients and their clinicians. MAT has the documented ability to analyze 2,500 whole exome datasets at 100x read depth in approximately seven minutes.

“We understand there are other companies analyzing genetic data to help determine health risks and treatment options,” noted Ian Jenkins, the company’s Chief Scientific Officer. “We think they make two critical mistakes. First, many of these competing tests are based on false assumptions regarding the diseases or treatments they are targeting, limiting the accuracy and value of their results. Second, they use ‘low resolution’ data to hit certain price points. This forces them to further narrow their focus, potentially missing critical data that could be significant to the individual being tested.”

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

Comments

Post comment

Jeff Moses on May 14
We've been asked if the company intends to pursue an IPO on a major exchange, such as NASDAQ.

Jeff Moses on May 14
The answer is yes. The company will be taking the appropriate steps, including undergoing PCAOB audit, securing an underwriter, etc. to pursue an IPO sometime in the future. While we cannot guarantee that we will reach IPO, or predict the market response to an IPO should we list on a major exchange, it is the company's intention to go public.

Bryan on February 14
Good morning! Looking forward to seeing the research come to life and the positive impact on people's health start to grow. When do you anticipate being able to start putting the Reg A+ investments to use?

Jeff Moses on February 14
Bryan, thanks for your interest in GATC Health. We will use "rolling closings" during this offering to make funds available to the company on an ongoing basis. This way, the funds are put to use as quickly as possible, rather than waiting until the end of the offering.

Offering Circular

Please read the Offering Circular here: Get Offering Circular

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM:

https://www.manhattanstreetcapital.com/offering-circular/27033

YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.